福建傲农生物科技集团股份有限公司关于公司股票可能被终止上市的第七次风险提示公告

Core Viewpoint - Fujian Aonong Biotechnology Group Co., Ltd. is at risk of being delisted due to negative net assets and consecutive annual losses from 2021 to 2023, leading to multiple risk warning announcements [2][4][8] Group 1: Reasons for Potential Delisting - The company reported negative net assets as of the end of 2023, resulting in a delisting risk warning effective from May 6, 2024 [2][4] - The company has incurred losses for three consecutive years (2021-2023), and the auditor issued a report with an emphasis on the company's ability to continue as a going concern [2][4] - If the company does not meet the criteria for lifting the delisting risk warning in the 2024 annual report, it faces termination of its listing [3][4] Group 2: Risk Warning Announcements - This announcement marks the seventh risk warning, as required by the Shanghai Stock Exchange regulations for companies facing delisting risks [2][8] - The company is obligated to issue risk warnings every 10 trading days until the annual report is disclosed [2][6] Group 3: Conditions for Lifting Delisting Risk - To lift the delisting risk warning, the company must report positive net assets and receive a standard unqualified audit opinion for the 2024 annual report [3][9] - The uncertainty remains regarding the lifting of the risk warning until the 2024 annual report is officially disclosed [3][9] Group 4: Other Matters - As of the announcement date, the audit for the 2024 annual report is ongoing, and final financial data will be based on the officially disclosed audited report [9]